Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine

Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

(2020) Hong Deng et al.   BMC Neurology

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

(2020) Messoud Ashina et al.   CEPHALALGIA

Nutrition and the ageing brain: Moving towards clinical applications

(2020) Emma Flanagan et al.   AGEING RESEARCH REVIEWS

Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans

(2020) Tessa de Vries et al.   PHARMACOLOGY & THERAPEUTICS

Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial

(2019) David W Dodick et al.   CEPHALALGIA

Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report

(2019) Stephen Aradi et al.   Journal of Stroke & Cerebrovascular Diseases

Recent Advances in Pharmacotherapy for Episodic Migraine

(2019) Calvin Chan et al.   CNS DRUGS

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Endogenous calcitonin gene-related peptide suppresses ischemic brain injuries and progression of cognitive decline

(2018) Liuyu Zhai et al.   JOURNAL OF HYPERTENSION

Migraine

(2018) David W Dodick   LANCET

History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment

(2018) Stewart J. Tepper   HEADACHE

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

(2018) Angelo Camporeale et al.   BMC Neurology

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2018) Spencer L James et al.   LANCET

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

(2018) Uwe Reuter et al.   LANCET

Epidemiology of Migraine

(2016) David S. Younger   NEUROLOGIC CLINICS

Wiping Out CGRP: Potential Cardiovascular Risks

(2016) Antoinette MaassenVanDenBrink et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP

(2014) Marcelo E Bigal et al.   CEPHALALGIA

Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide

(2014) Sarah Walter et al.   mAbs

Calcitonin Gene-Related Peptide: Physiology and Pathophysiology

(2014) F. A. Russell et al.   PHYSIOLOGICAL REVIEWS

Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain

(2013) Rodrigo Noseda et al.   PAIN

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

(2010) Jakob Møller Hansen et al.   CEPHALALGIA

CGRP receptor antagonism and migraine

(2010) Lars Edvinsson et al.   Neurotherapeutics

Possible sites of action of the new calcitonin gene-related peptide receptor antagonists

(2010) Sajedeh Eftekhari et al.   Therapeutic Advances in Neurological Disorders

The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs

(2009) Carlos M. Villalón et al.   PHARMACOLOGY & THERAPEUTICS